~~<i id='95E8F57B6A'><strike id='95E8F57B6A'><tt id='95E8F57B6A'><pre id='95E8F57B6A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

explore

author：explore 2025-10-04 11:35:50 - browse：24538

Adam's take main illustration — Molly Ferguson/STAT

I was wrong about Geron.

For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.

On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： FDA does about

leisure time

knowledge

focus

hotspot

explore

hotspot

JustinSullivan/GettyImagesFluvaccineappearstobeofferingreasonablelevelsofprotectionthiswinter,withpa

WSS

ALS groups 'won't be played again' by the FDA, drug sponsors

Pfizer highlights cancer drugs it thinks could reignite investor interest

RSV vaccines may be linked to small increased risk of developing GBS

House looks to weaken Medicare negotiation

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Just how powerful is the placebo effect?

Wikipedia

explore

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Change Healthcare cyberattack outage could last weeks

The cancer drug shortage isn’t new — and neither are the solutions

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Dobbs anniversary: the lost opportunity of abortion as health care

Study: New antibiotic targets gonorrhea as well as last existing drug

Trump demands the U.S. pay no more for drugs than other countries … again

Clinical trials giant ICON acquires HumanFirst

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Senate panel clears PBM, hopsital reforms

knowledge

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

An inside look at PIPEs, biotech's buzzy new financing tool

Extreme heat events are a public health emergency

UCSF medical school apologizes for unethical prisoner experiments

How to address the problem of discarded donor organs

Pfizer highlights cancer drugs it thinks could reignite investor interest

focus

hotspot

explore

hotspot